Details for Patent: 8,939,943
✉ Email this page to a colleague
Which drugs does patent 8,939,943 protect, and when does it expire?
Patent 8,939,943 protects EVZIO, EVZIO (AUTOINJECTOR), and NALOXONE HYDROCHLORIDE (AUTOINJECTOR), and is included in three NDAs.
This patent has thirty-five patent family members in ten countries.
Summary for Patent: 8,939,943
| Title: | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| Abstract: | Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH-adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition. |
| Inventor(s): | Eric S. Edwards, Evan T. Edwards, Mark J. Licata, Paul F. Meyers, Frank E. Blondino |
| Assignee: | EBAP Inc D/B/A STREAMLINE DESIGN , kaleo Inc |
| Application Number: | US14/062,516 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,939,943 |
|
Patent Claim Types: see list of patent claims | Composition; Device; |
Drugs Protected by US Patent 8,939,943
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kaleo Inc | EVZIO | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 205787-001 | Apr 3, 2014 | DISCN | Yes | No | 8,939,943 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Kaleo Inc | EVZIO (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 209862-001 | Oct 19, 2016 | DISCN | Yes | No | 8,939,943 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Kaleo Inc | NALOXONE HYDROCHLORIDE (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 215457-001 | Feb 28, 2022 | DISCN | Yes | No | 8,939,943 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,939,943
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011218756 | ⤷ Start Trial | |||
| Australia | 2012211307 | ⤷ Start Trial | |||
| Australia | 2012211320 | ⤷ Start Trial | |||
| Australia | 2015255197 | ⤷ Start Trial | |||
| Brazil | 112013018807 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
